Peptide Cell-Based Assays

Cell-based assays evaluate the biological activity of therapeutic peptides in a physiological context, providing functional potency data complementary to receptor binding studies. This protocol covers cell-based assay design, execution, data analysis, and regulatory requirements for peptide potency testing.

Cell-Based Assay Types

Assay Classification

Type	Readout	Throughput	Information	Application
Reporter gene assay	Luciferase/β-galactosidase	High	Transcriptional activity	Potency screening
Proliferation assay	Cell count/MTT/BrdU	Moderate	Mitogenic activity	Growth factor peptides
Calcium flux	Fluorescence (Ca²⁺ indicator)	High	GPCR signaling	GPCR agonist/antagonist
cAMP assay	Fluorescence/LRET	High	Gαs signaling	GLP-1, GHRH peptides
ERK phosphorylation	Western/ELISA	Moderate	MAPK signaling	Growth factor peptides
Cell migration	Wound healing/Boyden	Moderate	Motility activity	Wound healing peptides
Apoptosis assay	Annexin V/caspase	Moderate	Cell death	Oncology peptides

Reporter Gene Assay Protocol

Luciferase Reporter Assay

Step	Action	Conditions	Duration
1	Seed cells	10,000–20,000 cells/well	24 hours
2	Transfect reporter plasmid	Lipofection/electroporation	24–48 hours
3	Treat with peptide	8–10 concentrations (log dilution)	4–24 hours
4	Lyse cells	Passive lysis buffer	15 min
5	Add luciferase substrate	Luciferin + ATP	—
6	Measure luminescence	Luminometer	—
7	Calculate EC₅₀	Non-linear regression	—

β-Galactosidase Reporter Assay

Step	Action	Conditions	Duration
1	Seed cells	10,000–20,000 cells/well	24 hours
2	Transfect reporter plasmid	Lipofection	24–48 hours
3	Treat with peptide	8–10 concentrations	4–24 hours
4	Lyse cells	ONPG lysis buffer	15 min
5	Add substrate (ONPG)	4 mg/mL in Z-buffer	30 min
6	Stop reaction	1M Na₂CO₃	—
7	Measure absorbance	420 nm	—
8	Calculate EC₅₀	Non-linear regression	—

cAMP Assay Protocol

LRET-Based cAMP Assay (HTRF)

Step	Action	Conditions	Duration
1	Seed cells	10,000–20,000 cells/well	24 hours
2	Treat with peptide	8–10 concentrations	30 min
3	Add lysis buffer	supplemented with IBMX	15 min
4	Add cAMP-d2 conjugate	1:50 dilution	—
5	Add anti-cAMP cryptate	1:50 dilution	—
6	Incubate	Room temperature	1 hour
7	Read LRET	665/620 nm ratio	—
8	Calculate EC₅₀	Non-linear regression	—

ELISA-Based cAMP Assay

Step	Action	Conditions	Duration
1	Seed cells	10,000–20,000 cells/well	24 hours
2	Treat with peptide	8–10 concentrations	30 min
3	Lyse cells	0.1M HCl	10 min
4	Add to cAMP ELISA plate	100 μL/well	—
5	Add enzyme conjugate	50 μL/well	1 hour
6	Add substrate	TMB	15–30 min
7	Stop reaction	0.5M H₂SO₄	—
8	Measure absorbance	450 nm	—
9	Calculate EC₅₀	Standard curve	—

Calcium Flux Assay Protocol

Fluorescence-Based Calcium Flux

Step	Action	Conditions	Duration
1	Seed cells	30,000–50,000 cells/well	24 hours
2	Load calcium indicator	Fluo-4 AM (2–5 μM)	30–60 min
3	Wash cells	Hanks buffer	2×
4	Baseline measurement	37°C	30 sec
5	Add peptide agonist	8–10 concentrations	—
6	Measure fluorescence	Ex 488 nm, Em 520 nm	2–5 min
7	Add ionomycin (positive control)	1 μM	—
8	Calculate EC₅₀	Peak height/area	—

FLIPR-Based High-Throughput Calcium Flux

Parameter	Setting	Notes
Instrument	FLIPR Tetra	Automated liquid handling
Dye	Fluo-4 AM, Fluo-8 AM	Brighter indicators
Read rate	1–2 sec/well	High temporal resolution
Plate format	96 or 384 well	High throughput
Data output	Real-time fluorescence	Kinetic traces

Proliferation Assay Protocol

MTT Assay

Step	Action	Conditions	Duration
1	Seed cells	5,000–10,000 cells/well	24 hours
2	Treat with peptide	8–10 concentrations	48–72 hours
3	Add MTT	5 mg/mL (10 μL/well)	2–4 hours
4	Remove medium	Aspirate	—
5	Dissolve formazan	DMSO (100 μL/well)	10 min
6	Measure absorbance	570 nm (ref 630 nm)	—
7	Calculate EC₅₀	Non-linear regression	—

BrdU Incorporation Assay

Step	Action	Conditions	Duration
1	Seed cells	5,000–10,000 cells/well	24 hours
2	Treat with peptide	8–10 concentrations	24–48 hours
3	Add BrdU	10 μM final	2–4 hours
4	Fix cells	4% PFA	30 min
5	Denature DNA	2M HCl	30 min
6	Add anti-BrdU antibody	1:100	1 hour
7	Add secondary antibody	HRP-conjugated	30 min
8	Add substrate	TMB	15 min
9	Measure absorbance	450 nm	—

ERK Phosphorylation Assay Protocol

Western Blot-Based Assay

Step	Action	Conditions	Duration
1	Seed cells	100,000–200,000 cells/well	24 hours
2	Serum starve	0.5% FBS	16–24 hours
3	Treat with peptide	8–10 concentrations	5–30 min
4	Lyse cells	RIPA + phosphatase inhibitors	15 min
5	Run SDS-PAGE	10% gel	1–2 hours
6	Transfer to membrane	PVDF	1 hour
7	Block	5% BSA/TBST	1 hour
8	Probe with anti-pERK	1:1000	Overnight
9	Probe with anti-ERK	1:1000	1 hour
10	Detect	ECL chemiluminescence	—
11	Quantify	Densitometry	—

ELISA-Based Phospho-ERK Assay

Step	Action	Conditions	Duration
1	Seed cells	10,000–20,000 cells/well	24 hours
2	Serum starve	0.5% FBS	16–24 hours
3	Treat with peptide	8–10 concentrations	5–30 min
4	Lyse cells	ELISA lysis buffer	15 min
5	Add to anti-pERK plate	100 μL/well	Overnight
6	Add detection antibody	Biotinylated anti-ERK	1 hour
7	Add streptavidin-HRP	1:200	30 min
8	Add substrate	TMB	15 min
9	Measure absorbance	450 nm	—
10	Calculate EC₅₀	Standard curve	—

Cell Migration Assay Protocol

Wound Healing (Scratch) Assay

Step	Action	Conditions	Duration
1	Culture cells	Confluent monolayer	24–48 hours
2	Create wound	P200 pipette tip	—
3	Wash cells	PBS	2×
4	Add peptide	8–10 concentrations	—
5	Image wound	Phase contrast microscope	0, 6, 12, 24 hours
6	Measure wound closure	ImageJ analysis	—
7	Calculate migration rate	% closure vs. time	—

Boyden Chamber Assay

Step	Action	Conditions	Duration
1	Prepare chamber	8 μm pore membrane	—
2	Add cells to upper chamber	50,000–100,000 cells	—
3	Add peptide to lower chamber	8–10 concentrations	—
4	Incubate	37°C, 5% CO₂	12–24 hours
5	Remove non-migrated cells	Cotton swab	—
6	Fix and stain	Crystal violet	10 min
7	Count migrated cells	Microscope	5 fields/well
8	Calculate migration index	Treated / Control	—

Potency Assay Design

Assay Validation Parameters

Parameter	Requirement	Method
Accuracy	80–120%	Spike recovery
Precision	<20% CV	Replicate measurements
Linearity	r² >0.98	Standard curve
Range	EC₅₀ ± 2 log units	Concentration range
Specificity	No interference	Blank controls
Robustness	Z-factor >0.5	Plate quality

Reference Standard

Component	Requirement	Documentation
Primary standard	Fully characterized peptide	Certificate of analysis
Working standard	Calibrated against primary	Calibration curve
Positive control	Known agonist/antagonist	Control data
Negative control	Vehicle only	Background subtraction

Data Analysis

EC₅₀ Calculation

Method	Formula	Application
4-parameter logistic	Y = Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))	Standard analysis
Hill equation	Response = 100/(1+(EC₅₀/[Agonist])^n)	Simple cases
Linear regression	Standard curve	cAMP ELISA

Potency Comparison

Metric	Formula	Application
Relative potency	EC₅₀ (standard) / EC₅₀ (test) × 100%	Batch-to-batch comparison
Specific activity	Units/mg	Activity per mass
Fold induction	Treated / Untreated	Transcriptional activation

Regulatory Requirements

ICH Q6B Requirements

Requirement	Description	Documentation
Biological activity	Demonstrate mechanism of action	Potency assay report
Reference standard	Calibrated reference	Certificate of analysis
Lot release	Potency specification	Batch record
Stability	Potency over shelf life	Stability data

FDA Guidance

Requirement	Description	Documentation
Mechanism of action	Confirm biological activity	Functional assay data
Potency assay	Quantitative measure of activity	Validation report
Specificity	Confirm target engagement	Selectivity data
Correlation	Binding vs. functional activity	Correlation analysis

Troubleshooting

Problem	Possible Cause	Solution
High background	Non-specific activation	Serum reduce, optimize cells
Low signal	Insufficient stimulation	Increase peptide concentration
Variable EC₅₀	Cell passage number	Use early passage cells
Poor Z-factor	High variability	Optimize assay conditions
Cytotoxicity	High peptide concentration	Reduce concentration range
Plate edge effects	Evaporation	Use humidified incubator

References

1. Bhatt DL, et al. “Cell-based assays for peptide therapeutics.” Assay Drug Dev Technol 2015;13:1-12.
2. Haas AL, et al. “Reporter gene assays for GPCR ligands.” Methods Mol Biol 2018;1748:1-15.
3. Huang Y, et al. “Calcium flux assays for GPCR drug discovery.” Expert Opin Drug Discov 2019;14:1045-1057.
4. Xu Y, et al. “Cell-based potency assays for therapeutic peptides.” J Pharm Biomed Anal 2021;195:113897.
5. ICH Q6B. “Specifications: test procedures and acceptance criteria for biotechnological/biological products.” ICH Guidelines 1999.